Allos Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of anti-cancer therapeutics. It focuses on the development and commercialization of FOLOTYN (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the United States for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also developing FOLOTYN in other hematologic malignancies. The company has a strategic collaboration agreement with Mundipharma International Corporation Limited (Mundipharma) to co-develop FOLOTYN. Allos Therapeutics, Inc. has commercialization rights for FOLOTYN in the United States and Canada; and Mundipharma has rights to commercialize FOLOTYN in other countries. Allos Therapeutics, Inc. and Mundipharma are seeking regulatory approval to market FOLOTYN in the European Union and other geographies for the treatment of patients with relapsed or refractory PTCL; and are developing FOLOTYN in other potential indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado. As of September 4, 2012, Allos Therapeutics, Inc. operates as a subsidiary of Spectrum Pharmaceuticals, Inc.